VRCA FY 2023 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

VRCAVerrica Pharmaceuticals Inc.

$56M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-43.3% YoY

Gross Profit

$4M85.4% margin

Operating Income

-$66M-1283.4% margin

Net Income

-$67M-1307.5% margin

EPS (Diluted)

$-14.78

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$39M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$82M

Total Liabilities

$62M

Stockholders' Equity

$20M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$9M	-43.3%
Gross Profit	$4M	$8M	-47.3%
Operating Income	-$66M	-$21M	-208.8%
Net Income	-$67M	-$24M	-173.6%